摘要
肝细胞癌(hepatocellular carcinoma,HCC)是中国发病率及死亡率均较高的一种恶性肿瘤。肌少症(sarcopenia,SAR)在多种恶性肿瘤中的发病率均较高,且伴随更高的治疗不良反应率及更差的预后。HCC的发生发展和预后、对各种治疗的不良反应均与肌少症密切相关。本文就国内外关于HCC和肌少症间的相关研究进行综述,以寻找两者之间的关系,指导临床治疗。
Hepatocellular carcinoma(HCC)is a malignant tumor associated with high morbidity and mortality in China.The incidence of sarcopenia(SAR)in patients with various malignant tumors is relatively high,and it is accompanied by great severity of treatment toxicity and poor prognosis.The occurrence,development,and prognosis of HCC and adverse reactions to various treatments are closely associated with SAR.Here,we review the researches on HCC and SAR in China and abroad to clarify the relationship and subsequently provide reference for clinical treatment.
作者
刘建营
常静
Jianying Liu;Jing Chang(Department of Radiology,The Third Affiliated Hospital of Shandong First Medical University(Affiliated Hospital of Shandong Academy of Medical Sciences),Jinan 250031,China;Department of the Seventh Internal Medicine,The Third Affiliated Hospital of Shandong First Medical University(Affiliated Hospital of Shandong Academy of Medical Sciences),Jinan 250031,China)
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2020年第17期897-901,共5页
Chinese Journal of Clinical Oncology
基金
国家重点研发计划资助项目(编号:2018YFC2002000)资助。
关键词
肝细胞癌
肌少症
治疗
hepatocellular carcinoma(HCC)
sarcopenia(SAR)
treatment
